1. Cost Effectiveness of Nivolumab in Advanced Renal Cell Carcinoma
Michal Sarfaty, Moshe Leshno, Noa Gordon, Assaf Moore, Victoria Neiman, Eli Rosenbaum, Daniel A. Goldstein 
European Urology 
Volume 73, Issue 4, Pages (April 2018)
DOI: /j.eururo
Copyright © 2017 European Association of Urology Terms and Conditions

2. Fig. 1
Markov model.
European Urology  , DOI: ( /j.eururo )
Copyright © 2017 European Association of Urology Terms and Conditions

3. Fig. 2
Univariable sensitivity analyses. ICER=incremental cost-effectiveness ratio; QALY=quality-adjusted life-year.
European Urology  , DOI: ( /j.eururo )
Copyright © 2017 European Association of Urology Terms and Conditions

4. Fig. 3
Probability sensitivity analyses. QALY=quality-adjusted life-year.
European Urology  , DOI: ( /j.eururo )
Copyright © 2017 European Association of Urology Terms and Conditions